The medication from heartburn :: Consumers survey results of for 3 quarter of 2016

Consumers survey results of for 3 quarter of 2016 in category

Digestive system and hepatology / The medication from heartburn

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.	3	Phosphalugel (Astellas Europe)	41.18%	5

2.	1	Rennie (Bayer)	23.53%	2.86

2.		Алмагель (Balkanpharma)	23.53%	2.86

4.	3	Maalox (Sanofi)	17.65%	2.14

4.		Motilium (Johnson & Johnson)	17.65%	2.14

6.	3	Gaviscon (Гавіскон)	11.76%	1.43

6.	5	Гастромакс (Mili Healthcare)	11.76%	1.43

8.	5	Белалгін (Борщагівський ХФЗ)	5.88%	0.71

8.	4	Гастал (Pliva)	5.88%	0.71

8.	3	Домідон (Farmak)	5.88%	0.71

8.	4	Моторикс (Київський вітамінний завод)	5.88%	0.71

8.	2	Секрепат форте (Сперко Україна)	5.88%	0.71

8.	5	Текта Контрол (Takeda)	5.88%	0.71

–.	5	Домперидон-Стома (Стома)	0.00%	0

–.		Домрід (Kusum Pharm)	0.00%	0

–.	5	Мотинол (Pharmascience)	0.00%	0

–.		Пепсан (Майолі Україна)	0.00%	0

–.		Периліум (Genom Biotech)	0.00%	0

Using this rating is only possible with obligatory link to the source.

This rating was built as a result of the study of social preferences in 2016, under the “Favorites of Success” Contest in Ukraine and it’s the free information. In case of full or partial republishing of the information drawn from this rating, it is obligatory to mention the name of the “Favorites of Success” Contest in printed publications, or put an active hyperlink to this page in the electronic media.

Advanced reporting booklet about the study, including demographics of the respondents, by regional breakdown, information roll-call of ad hoc judges etc, can also be obtained from managers of the contest.